Platelet-rich plasma-derived extracellular vesicles delivered niraparib for ultrasound imaging and atherosclerosis treatment

Quick Facts

  • Publication title: Platelet-rich plasma-derived extracellular vesicles delivered niraparib for ultrasound imaging and atherosclerosis treatment
  • Journal: J Nanobiotechnology
  • Year: 2026
  • DOI: 10.1186/s12951-026-04076-z
  • PMID/PMCID: 41652437; PMC12977760

Research overview

Here, we developed NGPPEVs, a nanoplatform that employs PEVs to deliver niraparib, a PARP inhibitor, followed by encapsulation of Ca(HCO₃)₂ to generate gas within cells, thereby combining targeted therapy with ultrasound imaging capabilities. Collectively, NGPPEVs have great potential in the precise diagnosis and treatment of atherosclerosis.

Key findings

Macrophage-driven oxidative stress and chronic inflammation play pivotal roles in the progression of atherosclerosis.

Given the overactivation of poly (ADP-ribose) polymerase (PARP) in atherosclerosis, PARP inhibitors have potential therapeutic potential, but their efficacy is limited due to poor in vivo targeting.

Platelet-rich plasma-derived extracellular vesicles (PEVs), which inherently target inflammatory sites and mitigate oxidative stress, offer a promising delivery platform.

Here, we developed NGPPEVs, a nanoplatform that employs PEVs to deliver niraparib, a PARP inhibitor, followed by encapsulation of Ca(HCO₃)₂ to generate gas within cells, thereby combining targeted therapy with ultrasound imaging capabilities.

Echo Biotech Role

Echo Biotech contributed EV isolation and purification, cargo loading; the study also used or cited Exosupur®.

Related platforms: Exoomics®, Echosome®, Research Reagents & Tools

Related services and capabilities: EV Isolation & Purification, Small RNA / Cargo Loading, Research Reagent / Product Supply

Related products or reagents: Exosupur® EV Isolation/Purification Kit

References

Original publication: Platelet-rich plasma-derived extracellular vesicles delivered niraparib for ultrasound imaging and atherosclerosis treatment Journal of nanobiotechnology. 2026. DOI: 10.1186/s12951-026-04076-z. PMID/PMCID: 41652437; PMC12977760.